Tamoxifen News and Research

RSS

Tamoxifen is a drug used to treat certain types of breast cancer in women and men. It is also used to prevent breast cancer in women who have had ductal carcinoma in situ (abnormal cells in the ducts of the breast) and in women who are at a high risk of developing breast cancer. Tamoxifen is also being studied in the treatment of other types of cancer. It blocks the effects of the hormone estrogen in the breast. Tamoxifen is a type of antiestrogen. Also called tamoxifen citrate.

Researchers find genetic proof on how osteoarthritis destroys cartilage

A team of orthopaedic researchers has found definitive, genetic proof of how the most common form of arthritis destroys joint cartilage in nearly 21 million aging Americans, according to a study published online Sept. 2 in the Journal of Bone and Mineral Research. The findings serve as an important foundation for the design of new treatments for osteoarthritis (OA), researchers said.

2 Sep 2008

Risk of breast cancer recurring even after 5 years of therapy

New research has found that even after 5 years of systemic therapy, breast cancer patients still have a substantial risk of the disease recurring.

13 Aug 2008

Breast cancer patients still have risk of relapse after 5 years of systemic therapy

Breast cancer survivors continue to have a substantial risk of disease recurrence after five years of systemic therapy, according to a study published in the August 12 online issue of the Journal of the National Cancer Institute.

12 Aug 2008

FDA warns consumers about Baltimore Medicine Shoppe pharmacies

The U.S. Food and Drug Administration is warning consumers who filled prescriptions at The Medicine Shoppe pharmacies located at 8035A Liberty Road and 5900 Reisterstown Road in Baltimore that they may have received drugs that were either expired or suspected counterfeit.

10 Aug 2008

New hope for patients with breast cancers resistant to tamoxifen

Researchers have found a new family of therapeutic agents that interferes with the ability of estrogen to stimulate the growth of breast cancer cells. The results of the new study will be presented by Nicole Patterson at The Endocrine Society's 90th Annual Meeting in San Francisco.

16 Jun 2008

Novel agents found to inhibit growth of estrogen-dependent breast cancer cells

Researchers have discovered a new family of agents that inhibit the growth of estrogen-dependent breast cancer cells. The finding, described at a meeting of the Endocrine Society, has opened an avenue of research into new drugs to combat estrogen-dependent breast cancers.

16 Jun 2008

Nanoparticles trigger built-in cell-death signal to overcome drug resistance

One of the most vexing problems in treating cancer is the propensity of tumors to develop resistance to a wide range of anticancer drugs. Over 70 percent of ovarian cancer patients, for example, have drug-resistant tumors at the time of their initial diagnosis, and virtually all patients who relapse have drug-resistant tumors.

15 Jun 2008

Royal seal of approval for Breakthrough Breast Cancer's world-class research unit in Edinburgh

A pioneering new breast cancer research unit set up by leading UK charity Breakthrough Breast Cancer and the University of Edinburgh will be officially opened on Thursday 5 June 2008 by HRH The Prince of Wales (also known as The Duke of Rothesay while travelling in Scotland), the charity's Patron.

2 Jun 2008

First patient enrolled in phase III study of Bevacizumab and Trastuzumab in early breast cancer

A new international study for women with HER2-positive breast cancer is open for enrollment. The pivotal BETH (BEvacizumab and Trastuzumab Adjuvant Therapy in HER2-positive Breast Cancer) study is a Phase III clinical research trial that is investigating the benefits of combining two monoclonal antibodies, the anti-angiogenic, bevacizumab (Avastin) and the targeted therapy trastuzumab (Herceptin), together with chemotherapy for the treatment of patients with early stage HER2-positive breast cancer.

27 May 2008

Previously unseen switch regulates breast cancer response to estrogen

A tiny modification called methylation on estrogen receptors prolongs the life of these growth-driving molecules in breast cancer cells, according to research by scientists at Emory University's Winship Cancer Institute.

8 May 2008

Scientists discover 4th major set of common genetic variants linked to risk of estrogen receptor-positive breast cancer

Scientists from deCODE genetics report the discovery of two common single-letter variants (SNPs) on chromosome 5 of the human genome that are associated with risk of estrogen receptor-positive (ER+) breast cancer.

27 Apr 2008

Acupuncture provides effective relief from hot flushes for women taking tamoxifen after surgery for breast cancer

Acupuncture provides effective relief from hot flushes in women who are being treated with the anti-oestrogen tamoxifen following surgery for breast cancer, according to new research presented today (Friday) at the 6th European Breast Cancer Conference (EBCC-6) in Berlin.

18 Apr 2008

Mistletoe therapy in oncology

For many people, mistletoe conjures up images of Christmas holidays, but in parts of Europe, mistletoe extract is widely used as a therapy for cancer patients. However, a new review of studies finds only weak evidence that the treatment provides any benefit.

17 Apr 2008

No link between aromatase inhibitors and cardiovascular problems

New evidence has emerged that, contrary to some current fears, aromatase inhibitors (AIs) are not associated with an increased risk of heart problems in women who take them to prevent their breast cancer recurring.

17 Apr 2008

Biomarkers allow doctors to match therapy to patient

Genetic variations ensure that no two people are exactly alike, nor are their cancers.

13 Apr 2008

Chemotherapy-induced anemia increases risk of local breast cancer recurrence

Patients with breast cancer who developed anemia during chemotherapy had nearly three times the risk of local recurrence as those who did not, according to a study published in the April 1 issue of Clinical Cancer Research¸ a journal of the American Association for Cancer Research.

2 Apr 2008

Targeting aggressive breast cancers by putting them to sleep

It is well established that Id1, a gene normally produced only in embryonic development, is reactivated in many 'solid' cancers, or carcinomas.

26 Mar 2008

Cell therapies for diabetes, cancer

Therapies using stem cell transplants are advancing promising treatments for such conditions as Alzheimer's Disease, neurological diseases and spinal cord injury, and heart disease.

20 Mar 2008

Breast cancer more aggressive among overweight or obese women

Women with breast cancer have more aggressive disease and lower survival rates if they are overweight or obese, according to findings published in the March 15 issue of Clinical Cancer Research, a journal of the American Association for Cancer Research.

17 Mar 2008

Late treatment with letrozole (Femara) can reduce breast cancer recurrence risk

Treatment with the aromatase inhibitor letrozole (Femara) can reduce the risk of breast cancer recurrence even when initiated one to seven years after a course of tamoxifen therapy.

11 Mar 2008